Timing of the interim analysis in adaptive enrichment designs
Authors:
- 30 October 2017
- journal article
- research article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 28 (4) , 622-632
Abstract
With increasing interest in personalized medicine over the last years, study designs allowing to demonstrate efficacy in particular subgroups of the overall patient population become more important. Adaptive enrichment designs provide the possibility to both selecting the target population with the most promising treatment benefit and testing for efficacy within a single trial. Here, the target population is selected in a prespecified interim analysis. So far, it has not been very well investigated how timing of the interim analysis should be chosen. We investigate the impact of the interim analysis timing on power for the situation of a normally distributed outcome considering two different classes of selection rules. The interim selection is based either on the estimated effect difference between subgroup and total population or on absolute effect estimates. In this article, we demonstrate that there are indeed scenarios in which the timing of the interim analysis has a large impact on power. However, no universally applicable timing with favorable performance exist since power depends on treatment effects, subgroup prevalence, and especially the applied selection rule. Instead, the operating characteristics should be investigated for the specific scenario at hand to determine the most appropriate timing.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (05M13VHC)
This publication has 9 references indexed in Scilit:
- Adaptive Informational Design of Confirmatory Phase III Trials With an Uncertain Biomarker Effect to Improve the Probability of SuccessStatistics in Biopharmaceutical Research, 2016
- Decision Rules for Subgroup Selection Based on a Predictive BiomarkerJournal of Biopharmaceutical Statistics, 2014
- A conditional error function approach for subgroup selection in adaptive clinical trialsStatistics in Medicine, 2012
- An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints†Pharmaceutical Statistics, 2010
- Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncologyStatistics in Medicine, 2009
- Approaches to evaluation of treatment effect in randomized clinical trials with genomic subsetPharmaceutical Statistics, 2007
- Adaptive Sample Size Calculations in Group Sequential TrialsBiometrics, 1999
- An improved Bonferroni procedure for multiple tests of significanceBiometrika, 1986
- On closed testing procedures with special reference to ordered analysis of varianceBiometrika, 1976